Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fractyl Health, Inc. - Common Stock (NQ:GUTS)

0.9577 +0.1577 (+19.71%)
Streaming Delayed Price Updated: 1:24 PM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fractyl Health, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s ↗
Fractyl Health (NASDAQ:GUTS) reported one-year data from the randomized midpoint cohort of its REMAIN-1 study, saying its Revita procedure helped patients maintain a larger share of GLP-1-induced... 
Via MarketBeat
News headline image
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Inc (NASDAQ:GUTS) Q1 Earnings: Net Income Swing Masks Core Operating Burn as Key Revita Data Readout Looms ↗
Via Chartmill
Fractyl Health (NASDAQ:GUTS) Posts Narrower-Than-Expected Loss Ahead of Pivotal Trial Readout ↗
Via Chartmill
News headline image
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
Experienced market access leader joins to build reimbursement and health economic infrastructure for Revita® ahead of anticipated REMAIN-1 Pivotal Cohort topline data in early Q4 2026 
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Q1 Earnings Call Highlights ↗
Fractyl Health (NASDAQ:GUTS) said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement... 
Via MarketBeat
Topics Earnings
News headline image
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference
From Fractyl Health, Inc.
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
From DJS Law Group
Via Business Wire
News headline image
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
From The DJS Law Group
Via Business Wire
Top movers in Thursday's session ↗
Via Chartmill
Curious about the most active stocks on Thursday? ↗
Via Chartmill
Keep an eye on the top gainers and losers in Thursday's session. ↗
Via Chartmill
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study? ↗
Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation. 
Via Stocktwits
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
Holders will have until December 30, 2025 to exercise Tranche A Warrants at $1.05 per share, enabling up to $17.9 million in potential gross proceeds 
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health&#39;s Revita Procedure Helps Patients Keep Weight Off After Stopping GLP-1 Drugs ↗
Fractyl Health (NASDAQ: GUTS) released positive 6-month results from its REVEAL-1 study in obese patients who discontinued GLP-1 therapy. 
Via Benzinga
News headline image
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
From Fractyl Health, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.